Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143UH | ISIN: US50127T1097 | Ticker-Symbol: KUR
Tradegate
06.06.25 | 16:34
5,834 Euro
-1,15 % -0,068
1-Jahres-Chart
KURA ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
KURA ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,8206,04006.06.
5,7806,02206.06.

Aktuelle News zur KURA ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrKura Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
FrKura Oncology Grants Stock Options To New Hires Under Inducement Plan-
FrKura Oncology, Inc.: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)42SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
► Artikel lesen
KURA ONCOLOGY Aktie jetzt für 0€ handeln
MiCitizens JMP bekräftigt "Market Outperform"-Rating für Kura Oncology-Aktie5
MiKura Oncology Drug's Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia7
DiLeerink Partners reiterates outperform rating for Kura Oncology stock3
DiKura Oncology, Inc. - 8-K, Current Report2
DiKura Oncology reports positive trial results for AML treatment11
DiKura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting88- CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups...
► Artikel lesen
MoFDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin's Ziftomenib4
MoH.C. Wainwright bekräftigt Kaufempfehlung für Kura Oncology-Aktie2
MoH.C. WAINWRIGHT REITERATES BUY RATING ON KURA ONCOLOGY STOCK-
MoKura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML93 - New Drug Application based on positive results from the Phase 2 KOMET-001 trial - - FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 - - Potential first...
► Artikel lesen
27.05.Kura Oncology auf TD Cowen Summit: Strategische Innovationen bei Menin-Inhibitoren2
24.05.Cantor Fitzgerald behält Overweight-Rating für Kura Oncology-Aktie bei12
24.05.Cantor Fitzgerald maintains Overweight on Kura Oncology stock3
23.05.Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 20257
22.05.Kura Oncology to present trial results for AML treatment2
22.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting122- Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd - - Encore presentation planned at EHA 2025 Congress...
► Artikel lesen
14.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress176- Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th - - Updated dataset to be presented in oral presentation at EHA2025 Congress...
► Artikel lesen
Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2